BY EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: | ESSA Pharma Inc. |
Registration Statement on FormF-3 |
Submitted January 22, 2018 |
CIK No. 1633932 |
Ladies and Gentlemen:
ESSA Pharma Inc. (the “Company”) is filing herewith a resale registration statement on FormF-3 to replace three existing resale registrations (the “Existing Resale Registrations”) pursuant to the Company’s current registration statement on FormF-10 under the U.S./Canada Multijurisdictional Disclosure System (the “MJDS”). The Existing Resale Registrations expire on January 23, 2018 and the Company is not eligible to file a new registration statement on FormF-10. The Company is therefore switching from FormF-10 to FormF-3 to satisfy its continuing resale registration rights obligations.
* * * *
Licensed as foreign legal consultants
jurisdiction of primary qualification: New York
Securities and Exchange Commission
January 22, 2018
Page 2
Please telephone the undersigned at (416)777-4700 if you have any questions or require any additional information.
Very truly yours,
/s/ Riccardo Leofanti
Riccardo Leofanti
cc: David Wood, Chief Financial Officer, ESSA Pharma Inc.